NICEATM requests nominations/data
This article was originally published in The Rose Sheet
Executive Summary
National Toxicology Program Interagency Center for the Evaluation of Alternative Toxicological Methods requests nominations of experts to help evaluate the usefulness and limitations of Xenobiotic Detection Systems' stably-transfected estrogen receptor transcriptional activation assay (LUMI-CELL ER) and Certichem's cell proliferation assay (MCF-7). Center also asks for data generated through use of the in vitro tests - both used to determine whether chemicals interact with estrogen receptors - as well as relevant data for 78 reference substances recommended by NICEATM's Interagency Coordinating Committee on the Validation of Alternative Methods for use in validating such technologies. Possible candidates for international independent scientific review panel include experts in biostatistics, cellular biology, endocrinology, molecular genetics, regulatory toxicology, reproductive toxicology and test method validation. ICCVAM's efforts have facilitated the approval or endorsement of 31 alternative methods by federal regulatory bodies since 1997, significantly reducing animal use, the center notes
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.